冠状动脉鼻腔狭窄改善了耐火性心痛患者的冠状动脉微循环功能:一个多中心的前性INROAD研究
Matteo Tebaldi1, Gianluca Campo2, Fabrizio Ugo3
1Cardiology Unit, Ospedale degli Infermi, Faenza (RA), Italy (M.T.).
Circulation. Cardiovascular interventions
|January 16, 2024
概括
通过减速器植入,冠状动脉鼻收窄显著改善了冠状动脉微循环,并减少了耐火性心痛患者的心痛症状. 这种干预增强了微血管功能,提供了新的治疗见解.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 医疗器械 医疗器械
背景情况:
- 冠状动脉鼻狭窄的临床益处机制尚未完全理解.
- 研究冠状动脉缩对冠状动脉微循环功能的影响.
研究的目的:
- 评估冠状动脉缩对冠状动脉微循环功能指数的影响.
- 评估微循环阻力,冠状动脉流量储备和电阻阻比的变化.
主要方法:
- 在冠状动脉鼻减速器植入前和植入后4个月内,对耐火性心痛患者进行侵入性生理评估.
- 主要结局:微循环阻力指数 (IMR) 的变化.
- 二次结果:冠状动脉流量储量 (CFR) 和电阻比率 (RRR) 的变化.
主要成果:
- 在手术后IMR显著下降 (33.35±19.88至15.42±11.36,P<0.001).
- 71.4%的患者显示IMR显著降低;异常IMR从57%降低到19%.
- 冠状动脉流量储备和阻力比率有所改善;胸痛症状 (CCS类,SAQ分数) 也有所改善.
结论:
- 冠状动脉缩植入显著改善冠状动脉微循环功能参数.
- 这些发现表明,冠状动脉微血管功能障碍的治疗和改善心痛的潜力.
- 这项研究提供了对冠状动脉鼻狭窄的好处的见解,以缓解心痛.
关键词:
胸痛是一种心痛.冠状动脉副鼻的冠状动脉微循环是一种微循环.perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion 这是一个非常重要的方法,它可以让一个人觉得自己是个好的人,而不是一个好的人,而不是一个好的人.热稀释方式 热稀释方式相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
518
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Coronary Circulation
2.7K
The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
2.7K
Antianginal Drugs: Nitrates and β-Blockers
593
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
593
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432


